Reach Us +1-504-608-2390
Current Status of Plants as Vaccine Production Platforms | OMICS International | Abstract
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Current Status of Plants as Vaccine Production Platforms

Tetyana Rogalska, Justin Christopher Day, Mounir AbouHaidar and Kathleen Hefferon*
Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada
Corresponding Author : Kathleen Hefferon
Cell and Systems Biology
University of Toronto, Toronto
Ontario, Canada
Tel : (607) 387-6304
E-mail: Kathleen. [email protected]
Received October 25, 2011; Accepted December 12, 2011; Published December 13, 2011
Citation: Rogalska T, Day JC, AbouHaidar M, Hefferon K (2011) Current Status of Plants as Vaccine Production Platforms. J Clin Cell Immunol S4:003. doi:10.4172/2155-9899.S4-003
Copyright: © 2011 Rogalska T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Plant-derived biopharmaceuticals offer enormous potential as a cost-effective, rapid and safe means to produce vaccine and therapeutic proteins. Plant-made vaccines can be administered orally to elicit a mucosal immune response, and represent a method by which vaccine coverage can be improved for many who reside in developing countries. Vaccines such as these offer great promise on many levels, from providing relief to those who have little access to modern medicine, to producing large-scale stockpiles of vaccines available to offset global pandemics, and even to playing an active role in the battle against cancer. Plant-derived vaccines can both deliver an antigen to the mucosal immune system in the form of a food product, as well as prevent the antigen from degradation as it passes through the gastrointestinal tract. Both transgenic plants and plant virus expression vectors are routinely used to express biopharmaceutical proteins. The following review details recent advances concerning the production of vaccines against Hepatitis B virus, Human papilloma virus, Influenza virus and Non Hodgkins Lymphoma using plant expression platforms.